A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets.


Journal

PLoS biology
ISSN: 1545-7885
Titre abrégé: PLoS Biol
Pays: United States
ID NLM: 101183755

Informations de publication

Date de publication:
12 2021
Historique:
received: 19 03 2021
accepted: 22 11 2021
revised: 07 01 2022
pubmed: 29 12 2021
medline: 15 1 2022
entrez: 28 12 2021
Statut: epublish

Résumé

Over the past 20 years, 3 highly pathogenic human coronaviruses (HCoVs) have emerged-Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and, most recently, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-demonstrating that coronaviruses (CoVs) pose a serious threat to human health and highlighting the importance of developing effective therapies against them. Similar to other viruses, CoVs are dependent on host factors for their survival and replication. We hypothesized that evolutionarily distinct CoVs may exploit similar host factors and pathways to support their replication cycles. Herein, we conducted 2 independent genome-wide CRISPR/Cas-9 knockout (KO) screens to identify MERS-CoV and HCoV-229E host dependency factors (HDFs) required for HCoV replication in the human Huh7 cell line. Top scoring genes were further validated and assessed in the context of MERS-CoV and HCoV-229E infection as well as SARS-CoV and SARS-CoV-2 infection. Strikingly, we found that several autophagy-related genes, including TMEM41B, MINAR1, and the immunophilin FKBP8, were common host factors required for pan-CoV replication. Importantly, inhibition of the immunophilin protein family with the compounds cyclosporine A, and the nonimmunosuppressive derivative alisporivir, resulted in dose-dependent inhibition of CoV replication in primary human nasal epithelial cell cultures, which recapitulate the natural site of virus replication. Overall, we identified host factors that are crucial for CoV replication and demonstrated that these factors constitute potential targets for therapeutic intervention by clinically approved drugs.

Identifiants

pubmed: 34962926
doi: 10.1371/journal.pbio.3001490
pii: PBIOLOGY-D-21-00778
pmc: PMC8741300
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e3001490

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Cell. 2020 Dec 10;183(6):1520-1535.e14
pubmed: 33157038
Eur Respir J. 2004 Apr;23(4):620-8
pubmed: 15083765
Autophagy. 2007 Nov-Dec;3(6):581-5
pubmed: 17700057
J Gen Virol. 2005 May;86(Pt 5):1455-1465
pubmed: 15831958
Sci Rep. 2018 Nov 9;8(1):16597
pubmed: 30413791
mBio. 2017 Nov 21;8(6):
pubmed: 29162711
PLoS Pathog. 2011 Oct;7(10):e1002331
pubmed: 22046132
Nat Commun. 2013;4:1410
pubmed: 23361001
Viruses. 2021 Jan 18;13(1):
pubmed: 33477492
Nat Microbiol. 2020 Nov;5(11):1330-1339
pubmed: 32704094
Cell Microbiol. 2010 Jun;12(6):844-61
pubmed: 20088951
J Mol Evol. 1991 Feb;32(2):128-44
pubmed: 1901092
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):9864-9
pubmed: 27528677
Science. 2014 Jan 3;343(6166):84-87
pubmed: 24336571
Autophagy. 2013 Feb 1;9(2):164-74
pubmed: 23182945
Cell. 2021 Jan 7;184(1):106-119.e14
pubmed: 33333024
Cell Host Microbe. 2021 Feb 10;29(2):267-280.e5
pubmed: 33357464
Sci Rep. 2013;3:1055
pubmed: 23316280
Curr Top Microbiol Immunol. 2005;287:199-227
pubmed: 15609513
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
J Cell Sci. 2015 Feb 1;128(3):431-9
pubmed: 26046138
Nat Rev Mol Cell Biol. 2018 Jun;19(6):349-364
pubmed: 29618831
Elife. 2019 Jan 11;8:
pubmed: 30632963
J Med Virol. 2019 Mar;91(3):482-492
pubmed: 30267576
Front Genet. 2021 Jan 18;11:607479
pubmed: 33537060
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
Virus Res. 2014 May 12;184:44-53
pubmed: 24566223
PLoS Biol. 2008 Sep 16;6(9):e226
pubmed: 18798692
Genomics. 2000 Sep 15;68(3):283-95
pubmed: 10995570
J Virol. 1994 Oct;68(10):6523-34
pubmed: 8083990
Proc Natl Acad Sci U S A. 1967 Apr;57(4):933-40
pubmed: 5231356
Biology (Basel). 2020 Jul 28;9(8):
pubmed: 32731331
mBio. 2013 Feb 19;4(1):e00611-12
pubmed: 23422412
N Engl J Med. 2003 May 15;348(20):1967-76
pubmed: 12690091
Euro Surveill. 2012 Sep 27;17(39):
pubmed: 23041020
Antimicrob Agents Chemother. 2020 Jun 23;64(7):
pubmed: 32376613
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Virus Res. 2012 Apr;165(1):112-7
pubmed: 22349148
Nature. 2013 Mar 14;495(7440):251-4
pubmed: 23486063
J Virol. 2002 Apr;76(8):3697-708
pubmed: 11907209
Cell. 2021 Jan 7;184(1):76-91.e13
pubmed: 33147444
Front Cell Infect Microbiol. 2020 Feb 27;10:74
pubmed: 32175289
Clin Infect Dis. 2015 Feb 1;60(3):369-77
pubmed: 25323704
Cell. 2021 Jan 7;184(1):120-132.e14
pubmed: 33382968
J Virol. 2004 Sep;78(18):9977-86
pubmed: 15331731
EMBO Rep. 2017 Jun;18(6):947-961
pubmed: 28381481
Cell Host Microbe. 2010 Jun 25;7(6):500-8
pubmed: 20542253
Virology. 2018 Sep;522:46-55
pubmed: 30014857
Cell. 2021 Jan 7;184(1):133-148.e20
pubmed: 33338421
Nat Commun. 2019 Dec 18;10(1):5770
pubmed: 31852899
Genome Biol. 2014;15(12):554
pubmed: 25476604
PLoS Biol. 2019 Apr 1;17(4):e2007044
pubmed: 30933966
Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5
pubmed: 32735849
Cell. 2020 Aug 6;182(3):685-712.e19
pubmed: 32645325
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Nat Cell Biol. 2015 Mar;17(3):288-99
pubmed: 25720963
Nature. 2021 Jun;594(7862):246-252
pubmed: 33845483
EMBO Rep. 2018 Sep;19(9):
pubmed: 30126924
J Gen Virol. 2003 Sep;84(Pt 9):2305-2315
pubmed: 12917450
J Gastroenterol. 2003;38(6):567-72
pubmed: 12825133
Science. 2007 Nov 9;318(5852):977-80
pubmed: 17991864
Environ Int. 2019 Jan;122:263-269
pubmed: 30449631
J Gen Virol. 2011 Nov;92(Pt 11):2542-2548
pubmed: 21752960
Nat Methods. 2021 Jan;18(1):100-106
pubmed: 33318659
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Cell Discov. 2020 Oct 13;6:71
pubmed: 33083006
Nat Med. 2004 Apr;10(4):368-73
pubmed: 15034574
J Virol. 2005 Jan;79(2):884-95
pubmed: 15613317
J Gen Virol. 2003 Jul;84(Pt 7):1687-1699
pubmed: 12810862
J Biol Chem. 2004 Mar 12;279(11):10136-41
pubmed: 14699140
J Virol. 2006 Jun;80(12):5927-40
pubmed: 16731931
Proc Soc Exp Biol Med. 1966 Jan;121(1):190-3
pubmed: 4285768
Nature. 2020 Jun;582(7813):561-565
pubmed: 32365353
PLoS Genet. 2018 Aug 6;14(8):e1007583
pubmed: 30080879
Cell Mol Immunol. 2020 Aug;17(8):881-883
pubmed: 32555321
Cell. 1991 Aug 23;66(4):807-15
pubmed: 1715244
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
EMBO J. 2000 Nov 1;19(21):5720-8
pubmed: 11060023
Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):32105-32113
pubmed: 33239446
Nat Genet. 2021 Apr;53(4):435-444
pubmed: 33686287
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
J Cell Biol. 2018 Nov 5;217(11):3817-3828
pubmed: 30093494
Virus Res. 2017 Jan 15;228:7-13
pubmed: 27840112
J Microsc. 2013 Oct;252(1):89-91
pubmed: 23906423
Nature. 1992 Jun 4;357(6377):420-2
pubmed: 1350662

Auteurs

Annika Kratzel (A)

Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland.
Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
Graduate School for Biomedical Science, University of Bern, Bern, Switzerland.

Jenna N Kelly (JN)

Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland.
Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
European Virus Bioinformatics Center, Jena, Germany.

Philip V'kovski (P)

Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland.
Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.

Jasmine Portmann (J)

Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland.
Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.

Yannick Brüggemann (Y)

Department for Molecular & Medical Virology, Ruhr-Universität Bochum, Germany.

Daniel Todt (D)

European Virus Bioinformatics Center, Jena, Germany.
Department for Molecular & Medical Virology, Ruhr-Universität Bochum, Germany.

Nadine Ebert (N)

Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland.
Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.

Neeta Shrestha (N)

Division of Neurological Sciences, Vetsuisse Faculty, University of Bern, Bern, Switzerland.

Philippe Plattet (P)

Division of Neurological Sciences, Vetsuisse Faculty, University of Bern, Bern, Switzerland.

Claudia A Staab-Weijnitz (CA)

Comprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz-Center Munich, Member of the German Center of Lung Research (DZL), Munich, Germany.

Albrecht von Brunn (A)

Max von Pettenkofer-Institute, Ludwig-Maximilians-Universität München, Munich, Germany.
German Center for Infection Research, Munich Site, Munich, Germany.

Eike Steinmann (E)

Department for Molecular & Medical Virology, Ruhr-Universität Bochum, Germany.

Ronald Dijkman (R)

Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland.
Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
European Virus Bioinformatics Center, Jena, Germany.
Institute for Infectious Diseases, University of Bern, Bern, Switzerland.

Gert Zimmer (G)

Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland.
Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.

Stephanie Pfaender (S)

Department for Molecular & Medical Virology, Ruhr-Universität Bochum, Germany.

Volker Thiel (V)

Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland.
Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH